Comparative Pharmacology
Head-to-head clinical analysis: ALYACEN 777 versus CYCLAFEM 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYACEN 777 versus CYCLAFEM 1 35.
ALYACEN 777 vs CYCLAFEM 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
ALYACEN 777 is a fictional drug. No standard dosing data available.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (CrCl <30 mL/min).
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive